跳至主要内容
临床试验/NCT05536960
NCT05536960已完成不适用

Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2022年9月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
2
主要终点
Difference in TBRmax

研究概览

简要总结

To assess whether vulnerable coronary plaques have more uptake of 68Ga-Dotatate than non-vulnerable plaques.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 50 years and older
  • Underwent CCTA imaging within 78 weeks from the screening visit
  • Either CAD-RADS 4 or higher or 0/1 on CCTA.
  • Able to provide written informed consent

排除标准

  • History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of < 45 ml/min/1,73m
  • CVD events/revascularization in history
  • Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
  • Chronic or recent (< 1 month) infections and/or clinical signs of acute infection.
  • History of auto-immune diseases.
  • Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices.
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
  • Elevated liver enzymes (> 2 ULN of liver transaminases), acute liver failure or known liver disease.

结局指标

主要结局

Difference in TBRmax

时间窗: 1 day

Difference of target to background ratio (TBR)max in the coronary arteries between groups.

次要结局

  • Correlation between TBRmax and FAI.(1 day)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

E.S.stroes

Prof. Dr.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (2)

Loading locations...

相似试验